000128915 001__ 128915
000128915 005__ 20240228143357.0
000128915 0247_ $$2doi$$a10.1155/2016/6078473
000128915 0247_ $$2pmid$$apmid:27446966
000128915 0247_ $$2pmc$$apmc:PMC4942663
000128915 0247_ $$2ISSN$$a2314-7156
000128915 0247_ $$2ISSN$$a2314-8861
000128915 0247_ $$2altmetric$$aaltmetric:10020855
000128915 037__ $$aDKFZ-2017-04928
000128915 041__ $$aeng
000128915 082__ $$a610
000128915 1001_ $$00000-0002-2866-3901$$aKnippertz, Ilka$$b0
000128915 245__ $$aTranscriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation.
000128915 260__ $$aNew York, NY$$bHindawi$$c2016
000128915 3367_ $$2DRIVER$$aarticle
000128915 3367_ $$2DataCite$$aOutput Types/Journal article
000128915 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1526285532_12663
000128915 3367_ $$2BibTeX$$aARTICLE
000128915 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128915 3367_ $$00$$2EndNote$$aJournal Article
000128915 520__ $$aTo specifically target dendritic cells (DCs) to simultaneously express different therapeutic transgenes for inducing immune responses against tumors, we used a combined promoter system of adenoviral vectors. We selected a 216 bp short Hsp70B' core promoter induced by a mutated, constitutively active heat shock factor (mHSF) 1 to drive strong gene expression of therapeutic transgenes MelanA, BclxL, and IL-12p70 in HeLa cells, as well as in mature DCs (mDCs). As this involves overexpressing mHSF1, we first evaluated the resulting effects on DCs regarding upregulation of heat shock proteins and maturation markers, toxicity, cytokine profile, and capacity to induce antigen-specific CD8(+) T cells. Second, we generated the two-vector-based 'modular promoter' system, where one vector contains the mHSF1 under the control of the human CD83 promoter, which is specifically active only in DCs and after maturation. mHSF1, in turn, activates the Hsp70B' core promotor-driven expression of transgenes MelanA and IL-12p70 in the DC-like cell line XS52 and in human mature and hence immunogenic DCs, but not in tolerogenic immature DCs. These in vitro experiments provide the basis for an in vivo targeting of mature DCs for the expression of multiple transgenes. Therefore, this modular promoter system represents a promising tool for future DC-based immunotherapies in vivo.
000128915 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000128915 588__ $$aDataset connected to CrossRef, PubMed,
000128915 650_7 $$2NLM Chemicals$$aAntigens, CD
000128915 650_7 $$2NLM Chemicals$$aBCL2L1 protein, human
000128915 650_7 $$2NLM Chemicals$$aCD83 antigen
000128915 650_7 $$2NLM Chemicals$$aCytokines
000128915 650_7 $$2NLM Chemicals$$aDNA-Binding Proteins
000128915 650_7 $$2NLM Chemicals$$aImmunoglobulins
000128915 650_7 $$2NLM Chemicals$$aMART-1 Antigen
000128915 650_7 $$2NLM Chemicals$$aMembrane Glycoproteins
000128915 650_7 $$2NLM Chemicals$$aTranscription Factors
000128915 650_7 $$2NLM Chemicals$$abcl-X Protein
000128915 650_7 $$2NLM Chemicals$$aheat shock transcription factor
000128915 650_7 $$0187348-17-0$$2NLM Chemicals$$aInterleukin-12
000128915 7001_ $$aDeinzer, Andrea$$b1
000128915 7001_ $$00000-0002-3478-0741$$aDörrie, Jan$$b2
000128915 7001_ $$00000-0001-8236-9298$$aSchaft, Niels$$b3
000128915 7001_ $$00000-0002-1225-2593$$aNettelbeck, Dirk M$$b4
000128915 7001_ $$00000-0001-7187-6729$$aSteinkasserer, Alexander$$b5
000128915 773__ $$0PERI:(DE-600)2817541-4$$a10.1155/2016/6078473$$gVol. 2016, p. 1 - 17$$p1 - 17$$tJournal of Immunology Research$$v2016$$x2314-7156$$y2016
000128915 909CO $$ooai:inrepo02.dkfz.de:128915$$pVDB
000128915 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-1225-2593$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128915 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000128915 9141_ $$y2016
000128915 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128915 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128915 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128915 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000128915 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000128915 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000128915 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128915 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128915 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ IMMUNOL RES : 2015
000128915 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128915 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128915 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128915 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128915 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128915 9201_ $$0I:(DE-He78)F110-20160331$$kF110$$lOnkolytische Adenoviren$$x0
000128915 980__ $$ajournal
000128915 980__ $$aVDB
000128915 980__ $$aI:(DE-He78)F110-20160331
000128915 980__ $$aUNRESTRICTED